The FDA’s Center for Biologics Evaluation and Research (CBER) Office of Tissues and Advanced Therapies (OTAT) is hosting a virtual town hall to answer stakeholder questions related to gene therapy chemistry, manufacturing, and controls. This event is the first in a series to answer questions from stakeholders about a variety of topics.
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/G6PvDWx
No comments:
Post a Comment